Acute Myeloid Leukemia (AML) is a type of blood cancer. This study is exploring new treatments based on genes, called biomarkers, in people with AML. Biomarkers are tiny signs in the body that can help doctors decide the best way to treat the cancer. The trial is in two phases, called Phase 1b and Phase 2, and is part of a bigger plan called the "Master Protocol."
People who join will be put into different groups based on their type of AML. Some groups will test new treatments, while others will include patients who don’t fit any specific group. This study is for adults, mostly 60 years or older, with specific genetic traits.
- Study Duration: The study may last several months as it involves multiple phases.
- Visits: Participants need regular visits for treatment and check-ups.
- Risks: There may be side effects from the new treatments, and not all patients will receive the same therapy.
People with serious health problems or certain types of AML are not eligible. Participants must be able to understand and agree to the study rules.